Trials Sponsors Conditions Drugs Pricing

Conditions

Myeloid Leukemia, Chronic

Keywords

NIlotinib , Suboptimal Response , Imatinib

Outcome Measures

Primary Outcomes (1)

The primary efficacy variable of this study is the overall Major molecular response at 12 month after starting Nilotinib 300mg twice daily for patient who suboptimally responded to Imatinib as per the ELN guidelines
12 Months

Secondary Outcomes (6)

Rate of cytogenetic response (complete cytogenetic response CCyR and Major cytogenetic response MCyR) and Major molecular response MMR at 3, 6 and 12 months of starting Nilotinib in patients who had a suboptimal response on Imatinib.
12Months
Rate of CCyR at 6 months and MMR at 6 and 12 months from Nilotinib dose escalating to 400 mg BID.
12 months
Rate and duration of Complete Hematologic Response CHR.
12 months
Rate of CMR at 12 months of Nilotinib.
12 months
Comparison of FISH results with conventional cytogenetics at 3, 6 & 12 months.
12
+1 more secondary outcomes

Other Outcomes (1)

Mutational analysis for the patients with suboptimal response at the pre defined end points as per the ELN guidelines.
12 months

Study Arms (1)

Nilotinib 300 mg

EXPERIMENTAL

Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg but show sub-optimal response on Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg twice daily and will be assessed for timely. In the absence of safety concerns, nilotinib could be escalated to 400 mg twice daily if patients had not obtained any of the following milestones: 1. BCR-ABL1 transcript level ≤ 10% at 3 months; 2. CCyR at 6 months, 3. BCR/ABL1 ≤ 1% at 6 months 4. MMR at 12 months, or 5. if they showed loss of cytogenetic or molecular response or disease progression at any time. Failure and thus, stopping nilotinib will be considered if any of above milestones happened while on the 400mg twice daily dose.

Drug: Nilotinib 300 mg.

Interventions

Nilotinib 300 mg.Drug

Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as: Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript \> 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at \> 12 months; i.e (BCR-ABL1 0.1 -1%)

Also known as: Tasigna 300 mg

Nilotinib 300 mg

Eligibility Criteria

Age18 Years - 90 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Written informed consent prior to any study procedures being performed.
Age 18 or above of male or female CML patients in chronic phase.

Sponsors & Collaborators

Novartis
Industrycollaborator
King Abdullah International Medical Research Center
Otherlead

Study Sites (2)

National Guard Hospital

Riyadh, Central, 11426, Saudi Arabia

King Fahad specialist Hospital

Dammam, Eastern Province, Saudi Arabia

MeSH Terms

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

nilotinib

Condition Hierarchy (Ancestors)

Leukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsMyeloproliferative DisordersBone Marrow DiseasesHematologic DiseasesHemic and Lymphatic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Dr. Ahmad S. Alaskar, MD,FACP,FRCP
King Abdulaziz Medical City
PRINCIPAL INVESTIGATOR

Enrollment

98 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

February 27, 2014

First Posted

March 13, 2014

Study Start

March 2013

Date type not reported

This date has not been verified as actual or estimated.

You may not qualify if:

Previous Exposure to Tyrosine Kinase Inhibitor (TKI) other than Imatinib for more than 2 weeks
Patients who are already participating in any other clinical trial.Patients who were not compliant to Imatinib therapy.
Optimal response to Imatinib therapy as determined by any one of the criteria: 3.1. CCyR or PCyR at 3 months (Ph+ metaphases in BM ≤ 35 %). 3.2. BCR-ABL1 transcript ≤ 10 % at 3 months. 3.3. CCyR at 6 months (Ph+ metaphases in BM 0 %). 3.4. BCR-ABL1 transcript \< 1% at 6 months. 3.5. BCR-ABL1 transcript ≤ 0.1 % at 12 months. 3.6. BCR-ABL1 transcript ≤ 0.1 % at any time.
Failure response to Imatinib therapy as per ELN guidelines 2013 as determined by any of the criteria: 4.1. Non- complete hematologic response (Non- CHR) or no cytogenetic response CyR at 3 months (Ph+ metaphases in BM \> 95 %). 4.2. Less than Partial cytogenetic response PCyR at 6 months (Ph+ metaphases in BM \> 35%). 4.3. BCR-ABL1 transcript \>10 % at 6 months. 4.4. Less than complete cytogenetic response CCyR at 12 months (Ph+ metaphases in BM \> 0 %). 4.5. BCR-ABL1 transcript \>1 % at 12 months. 4.6. Loss of CHR or loss of CCyR or confirmed loss of MMR\* or development of partially imatinib - sensitive BCR-ABL mutation or CCA in Ph- positive cells at any time.
Pregnant or lactating females
Patients with prolonged QT intervals
Patient with history of pancreatitis
Previously documented T315I mutations;
Uncontrolled congestive heart failure or hypertension;
Myocardial infarction or unstable angina pectoris within past 12 months;
Significant arrhythmias, including history or presence of clinically significant ventricular or atrial tachyarrhythmias, clinically -significant bradycardias, long QT syndrome and/or corrected QT interval (QTc) \> 450 msec on screening ECG. Patients with complete LBBB (Left Bundle Branch Block);
Patients concurrently on strong CYP3A4 inhibitors.
Other concurrent uncontrolled medical conditions (e.g. uncontrolled diabetes, active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol;
Impaired gastrointestinal function or GI disease that may alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting and diarrhea, malabsorption syndrome, small bowel resection or gastric by-pass surgery);
Patients with another primary malignancy that is currently clinically significant or requires active intervention.

Study Stopped

Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Other Outcomes (1)

Study Arms (1)

Nilotinib 300 mg

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Other Outcomes (1)

Study Arms (1)

Nilotinib 300 mg

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations